Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesMasitinib in the treatment of active rheumatoid arthritis: Results of a multicentre, open-label, dose-ranging, phase 2a study
Arthritis Research & Therapy, 06/25/09
Tebib J et al. – Study reports that treatment with masitinib (AB1010; a potent and selective protein tyrosine kinase inhibitor of c-KIT) improved DMARD-refractory active rheumatoid arthritis (RA). Following an initial high incidence of mostly mild to moderate side effects during the first 12 weeks of treatment, masitinib appears to be generally well tolerated. This, together with a sustainable efficacy response, suggests that masitinib is suitable for long-term treatment regimens.
Methods- An evaluation of safety and efficacy of masitinib in the monotherapy treatment of DMARD-refractory RA
- In a dose-ranging, phase 2a trial masitinib was administered orally to 43 pts at initial randomised dosing levels of 3 and 6 mg/kg/d over a 12-wk period
- Dose adjustment was permitted based upon tolerability and response criteria
- Efficacy was assessed via:
- ACR 20%/50%/70% improvement criteria (ACR20/50/70) responses
- Disease activity score using 28 joint counts (DAS28)
- Index of improvement in RA (ACRn), and
- C-reactive protein (CRP) improvement
- relative to baseline at week 12
- Improvement was observed in all efficacy endpoints, including ACR20/50/70 scores of 54%, 26% and 8%, respectively
- Reduction in CRP level by >50% for half the population
- This improvement was sustainable throughout an extension phase (>84 wks) and was also independent of initial DMARD resistance
- Incidence of AEs was high (95%), although the majority were of mild or moderate severity
- AEs declined in frequency observed after 12 wks of treatment
- 2 nonfatal serious AEs were reported
- An initial dosing level of 6.0 mg/kg/d administered orally in 2 daily intakes was the most appropriate, based upon potency and tolerability trends
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparison of autoinflammation and autoimmunity using TRAPS and rheumatoid arthritis as prototypes of these conditions
International Journal of Clinical Rheumatology, 12/04/09
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
Arthritis Research & Therapy, 11/25/09
No evidence for association of the KLF12 gene with RA in a large UK cohort of >7,000 samples.
Annals of Rheumatic Diseases, 11/23/09
Sponsor
Article Search
Sponsor